As the number of people suffering from non-communicable diseases (NCDs) continues to rise, particularly in low and low-to-middle income countries, mortality and disability rates stemming from NCDs are also projected to rise. In fact, NCDs are responsible for 60 percent of deaths worldwide – that’s 36 million deaths per year.
The good news is that twenty-two leading biopharmaceutical companies, in partnership with the World Bank Group and the Union for International Cancer Control are uniting to combat NCDs, including cancer, diabetes, heart disease, chronic respiratory diseases and more. Known as Access Accelerated, the global initiative takes on the United Nation’s Sustainable Development Goal 3, which aims to reduce premature deaths from NCDs by one-third by 2030.
Access Accelerated will choose a handful of low-income and lower-middle income countries where it will pilot programs focused on diagnosis, screening and delivery for prevention and care through the development of cost-effective, easily transmittable medicines and vaccines. The initiative will scale the successful tactics to the larger, global community. Access Accelerated plans to combat the financial and infrastructure obstacles developing nations face – increasing the accessibility of medicines and solutions for people who need them most.
Preventing and curing the world’s NCDs take more than medicine, and requires a unified, global effort by many groups. Access Accelerated leverages the capabilities of each of its participating organizations to offer a comprehensive approach to solving some of the world’s toughest health challenges.